Pharma Surge
Pharma Surge
Intelligence Layer
🇺🇸·Apr 9Research

Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer

Publisher

F
Frazier Life Sciences

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
Frazier Life Sciences
Region
USA
Scope
Research
Published
April 9, 2026

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on frazierls.com

Leave the platform to read the original full article on the publisher site.

Source: Frazier Life Sciences

Scope: Research

Open original article
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer | Pharma Surge